Investigators at Saint Louis University propose to transition our research on HIV vaccine development as an AVEU to the HVTN. A dedicated and experienced team of investigators and staff will contribute to the research agenda of the HVTN through work with the Vaccine Leadership Group (VLG) and through protocol development and implementation. Investigators at SLU have an excellent track record at volunteer recruitment and retention, innovation in dealing with volunteers' safety issues (such as antibody positivity after vaccination), full compliance with protocols, efficient reporting of data to the network, timely publication of results, and strong basic science research related to HIV vaccine immune responses This application summarizes our track record to date and key findings from our phase I and phase II studies of HIV vaccines. In parallel we have conducted research on the reasons why minorities may be reluctant to participate in clinical studies, and this proposal describes our success at overcoming some obstacles to minority recruiting. This proposal summarizes the results of phase II studies in higher risk groups and describes ongoing studies to select the most immunogenic canarypox vector for larger clinical trials. These larger trials will obtain preliminary data on efficacy on live vectors expressing HIV antigens vs. subunit vaccines vs. both live vector and subunit vaccines vs. placebo. These studies will provide us with the opportunity to assess possible immune correlates of protection from HIV. We summarize phase I protocol development for newer vaccines including vectors or polynucleotide vaccines. A point by point discussion of the 15 requirements set forth in this RFA summarizes our approach to significant regulatory and human studies issues, the organization and mission of the SLU Community Advisory Board, and the quality assurance plan of this unit. We conclude with a description of a potential expansion site at UIC for phase III studies in women at high risk from heterosexual transmission. This mode of transmission is less prevalent in the US than in developing nations and we believe this expansion site will enhance the HVTN's ability to pilot studies for international phase III trials, as well as contribute large numbers of subjects to phase III trials.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-HSD-A (M1))
Program Officer
Flores, Jorge E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Saint Louis University
Internal Medicine/Medicine
Schools of Medicine
Saint Louis
United States
Zip Code
Frey, Sharon E; Peiperl, Laurence; McElrath, M Juliana et al. (2014) Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. Clin Vaccine Immunol 21:1589-99
Gorse, Geoffrey J; Newman, Mark J; deCamp, Allan et al. (2012) DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults. Clin Vaccine Immunol 19:649-58
Fitzgerald, D W; Janes, H; Robertson, M et al. (2011) An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 203:765-72
Barnabas, Ruanne V; Wasserheit, Judith N; Huang, Yunda et al. (2011) Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). J Acquir Immune Defic Syndr 57:238-44
Goepfert, Paul A; Elizaga, Marnie L; Sato, Alicia et al. (2011) Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 203:610-9
Keefer, Michael C; Frey, Sharon E; Elizaga, Marnie et al. (2011) A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948-58
Gorse, Geoffrey J; Baden, Lindsey R; Wecker, Margaret et al. (2008) Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26:215-23
Gorse, Geoffrey J; Simionescu, Ramona E; Patel, Gira B (2006) Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol 13:26-32
de Bruyn, Guy; Hudgens, Michael G; Sullivan, Patrick S et al. (2005) Participant retention in clinical trials of candidate HIV vaccines. J Acquir Immune Defic Syndr 39:499-501
Goepfert, Paul A; Horton, Helen; McElrath, M Juliana et al. (2005) High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192:1249-59

Showing the most recent 10 out of 19 publications